IL6 and COVID-19: Nevertheless, ongoing clinical trials are evaluating the efficacy and safety of this drug in COVID-19 (NCT04486521), (NCT04329650) (Martinez, 2022; Anti-IL6 and Corticosteroid Monotherapy, 2022).